Author: Qingyang Xu; Shomesh Chaudhuri; Danying Xiao; Andrew W Lo
Title: Bayesian Adaptive Clinical Trials for Anti-Infective Therapeutics during Epidemic Outbreaks Document date: 2020_4_14
ID: 20hk99h4_3
Snippet: For severe diseases with no curative treatments, such as pancreatic cancer, patients tend to tolerate a higher Type I error of accepting an ineffective therapy in exchange for a lower Type II error of rejecting an effective therapy as well as expedited approvals of potentially effective treatments. Based on this observation, a patient-centered Bayesian protocol was proposed (Isakov et al., 2018; Montazerhodjat et al., 2017) that incorporates pati.....
Document: For severe diseases with no curative treatments, such as pancreatic cancer, patients tend to tolerate a higher Type I error of accepting an ineffective therapy in exchange for a lower Type II error of rejecting an effective therapy as well as expedited approvals of potentially effective treatments. Based on this observation, a patient-centered Bayesian protocol was proposed (Isakov et al., 2018; Montazerhodjat et al., 2017) that incorporates patient values into clinical trial design and identify the optimal balance between the possibilities of false positives (Type I error) and false negatives (Type II error). For more severe diseases, this protocol sets a tolerated Type I error rate much larger than the traditional 5% threshold, which leads to higher rates of approvals and expedited approval decisions.
Search related documents:
Co phrase search for related documents- approval decision and optimal balance: 1
- approval decision and patient value: 1
- approval decision and Type error: 1, 2, 3
- approval decision and type II error: 1
- Bayesian protocol and optimal balance: 1
- Bayesian protocol and trial design: 1
- Bayesian protocol and Type error: 1
- clinical trial design and effective therapy: 1, 2
- clinical trial design and false negative: 1
- clinical trial design and false positive: 1, 2
- clinical trial design and high rate: 1, 2, 3
- clinical trial design and severe disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- clinical trial design and trial design: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- clinical trial design and Type error: 1, 2, 3
- clinical trial design and type II error: 1
- curative treatment and effective therapy: 1, 2, 3, 4
- curative treatment and high rate: 1, 2, 3, 4, 5, 6, 7, 8
- curative treatment and ineffective therapy: 1
Co phrase search for related documents, hyperlinks ordered by date